We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vericel (VCEL) Flat As Market Sinks: What You Should Know
Read MoreHide Full Article
Vericel (VCEL - Free Report) closed the most recent trading day at $17.10, making no change from the previous trading session. This change was narrower than the S&P 500's 1.91% loss on the day. Meanwhile, the Dow lost 2.02%, and the Nasdaq, a tech-heavy index, lost 2.26%.
Heading into today, shares of the cell therapy maker had gained 1.66% over the past month, outpacing the Medical sector's gain of 0.32% and the S&P 500's loss of 2.51% in that time.
VCEL will be looking to display strength as it nears its next earnings release, which is expected to be March 4, 2019. The company is expected to report EPS of $0.05, up 66.67% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $29.84 million, up 27.77% from the year-ago period.
VCEL's full-year Zacks Consensus Estimates are calling for earnings of -$0.29 per share and revenue of $89.36 million. These results would represent year-over-year changes of +42% and +39.78%, respectively.
Investors might also notice recent changes to analyst estimates for VCEL. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. VCEL is holding a Zacks Rank of #1 (Strong Buy) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow VCEL in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vericel (VCEL) Flat As Market Sinks: What You Should Know
Vericel (VCEL - Free Report) closed the most recent trading day at $17.10, making no change from the previous trading session. This change was narrower than the S&P 500's 1.91% loss on the day. Meanwhile, the Dow lost 2.02%, and the Nasdaq, a tech-heavy index, lost 2.26%.
Heading into today, shares of the cell therapy maker had gained 1.66% over the past month, outpacing the Medical sector's gain of 0.32% and the S&P 500's loss of 2.51% in that time.
VCEL will be looking to display strength as it nears its next earnings release, which is expected to be March 4, 2019. The company is expected to report EPS of $0.05, up 66.67% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $29.84 million, up 27.77% from the year-ago period.
VCEL's full-year Zacks Consensus Estimates are calling for earnings of -$0.29 per share and revenue of $89.36 million. These results would represent year-over-year changes of +42% and +39.78%, respectively.
Investors might also notice recent changes to analyst estimates for VCEL. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. VCEL is holding a Zacks Rank of #1 (Strong Buy) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow VCEL in the coming trading sessions, be sure to utilize Zacks.com.